Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegylated recombinant human hyaluronidase - Halozyme Therapeutics/Nektar Therapeutics

Next Previous
X
Search
Drug Profile

Pegylated recombinant human hyaluronidase - Halozyme Therapeutics/Nektar Therapeutics

Alternative Names: PEG PH20; PEG rHuPH-20; pegvorhyaluronidase alpha; Pegylated hyaluronidase; PEGylated reombinant human hyaluronidase - Halozyme; Pegylated rHuPH20

Latest Information Update: 15 Jun 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Halozyme Therapeutics
  • Developer Eisai Co Ltd; Genentech; Halozyme Therapeutics; Scripps Health; University of California at San Francisco
  • Class Antineoplastics; Glycoside hydrolases; Polysaccharide lyases
  • Mechanism of Action Hyaluronic acid modulators; Hyaluronidase replacements; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer; Cholangiocarcinoma; Gallbladder cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 05 Apr 2024 Interim adverse events and efficacy data from the phase-Ib/II MORPHEUS-PDAC trial in Pancreatic cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 09 Nov 2023 Southwest Oncology Group in collaboration with Halozyme Therapeutics completes a phase Ib/II trial in Pancreatic cancer (Combination therapy, First-line therapy, Metastatic disease, Late-stage disease) in USA (NCT01959139)
  • 25 Sep 2020 Genentech terminates phase II trial in Pancreatic cancer (Neoadjuvant therapy, Combination therapy, First-line therapy) in USA due to loss of funding (IV) (NCT03979066)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top